摘要 ： 招标文件新增两项内容：其一为"异常低价投标审查"；其二为"海关'两新'项目廉政承诺协议"。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 此前，海关总署公布了2 3个仪器采购项目，计划采购PCR仪、X射线荧光光谱仪、蛋白质测定仪等设备共计11 0 8台， 总预算达8 . 9 2亿元。自2 0 2 5年9月起，相关招标工作陆续启动。 自2 0 2 5年9月起，相关招标采购工作陆续启动。在超级微波消解仪、离子色谱仪、气相色谱仪等项目的投标人资格条件 中，均明确注明 "不接受进口产品投标" ，并对进口产品作出清晰界定，即 "通过中国海关报关验放进入中国境内且产 自关境外的产品" 。该政策引发国内外厂商高度关注，一方面各方积极争取采购订单，另一方面也密切关注海关在仪器 国产化采购方面的具体执行方式。 近期，离子色谱、原子吸收分光光度计、微波消解仪等关键检测仪器的招标结果逐步公布。 11月1 9日， 海关总署就多项仪器采购项目发布变更公告 ，涉及能量色散X射线荧光光谱仪、蛋白质测定仪、高效液相 色谱-三重四极杆质谱仪以及基因测序仪等。为更 ...

Core Points - The article discusses the procurement project by the General Administration of Customs for 25 gas chromatography-triple quadrupole mass spectrometers with a budget of 36.62 million yuan [1][2] - The overall procurement plan includes 23 projects with a total of 1,108 instruments and a total budget of 891.548 million yuan, expected to be procured between July and October 2025 [2] Procurement Details - The procurement project is specifically for gas chromatography-triple quadrupole mass spectrometers, with a total of 25 units planned for purchase [1][4] - The budget for this specific project is set at 36.62 million yuan [1][4] - The project explicitly states that imported products are not accepted for bidding, which includes products that have been imported through Chinese customs [2][10] Bidding Process - Bidding documents can be obtained online from November 19 to November 26, 2025, with the opening of bids scheduled for December 10, 2025 [4][16] - The bidding process will be conducted online, and paper submissions will not be accepted [16][19] - Potential bidders must register on the customs procurement platform and download the bidding documents after successful registration [12][13] Eligibility Criteria - Bidders must comply with the relevant laws and regulations of the People's Republic of China regarding government procurement [7][8] - The project is open only to small and medium-sized enterprises, and joint bids are not allowed [11][9]

Core Viewpoint - The Ministry of Finance has issued a notice to address the issue of abnormally low bids in government procurement, marking a significant shift from a focus on low prices to an emphasis on quality and effectiveness in the medical equipment market [4][7]. Group 1: Government Procurement Reforms - The new regulations aim to combat the persistent issue of low-price bidding in the medical equipment sector, which has been detrimental to product quality and patient safety [9][10]. - The notice introduces a closed-loop system focusing on "source control, process review, and post-responsibility," addressing previous challenges in identifying and managing low-price bids [10][12]. Group 2: Impact on Medical Equipment Market - The introduction of a full lifecycle cost concept in procurement will require consideration of ongoing maintenance and consumable costs, thereby preventing the common practice of low initial bids followed by high consumable prices [12][13]. - The new rules will enhance scrutiny of low-price bids, with specific criteria established to identify and reject bids that are excessively low compared to market averages [12][13]. Group 3: Industry Dynamics and Competition - The reforms are expected to shift the competitive landscape, pushing domestic companies to transition from a price-based strategy to one focused on value [14]. - Foreign brands may benefit from the new emphasis on quality and service, as their technological advantages can be better recognized under the new evaluation criteria [14][15]. Group 4: Innovation and Market Growth - The reduction of low-price competition is anticipated to lead to increased investment in research and development, fostering innovation within the industry [15]. - With a projected budget of 19.6 billion for medical equipment updates, the new policies are expected to direct funds towards high-quality products and services, enhancing the efficiency of public healthcare resource allocation [15].

Core Viewpoint - The Ministry of Finance has issued a notice to address the issue of abnormally low bids in government procurement, signaling a shift from a focus on low prices to quality and effectiveness in the medical equipment market [1][3]. Government Procurement Reform - The new draft aims to create a systematic governance framework to tackle the persistent issue of low-price bidding in government procurement, particularly in the medical sector [3][5]. - Pilot programs have been initiated in various free trade zones and cities to address the problem of abnormal low-price bids [3]. Abnormal Low-Price Bidding Issues - The medical equipment sector has seen extreme price reductions, with bids often significantly below market rates, raising concerns about quality and safety [4][5]. - Examples include a bid of 1,000 yuan for a 3 million yuan project, highlighting the risks associated with such low bids [4]. Impact on Industry Competition - Abnormal low-price bidding has led to a decline in the quality of medical equipment and services, affecting patient safety and healthcare outcomes [5]. - The competition has forced some manufacturers to shift focus from R&D to lower-end products, hindering the advancement of domestic brands [5]. New Procurement Guidelines - The draft emphasizes a full lifecycle cost approach, requiring that ongoing maintenance and consumable costs be considered in bid evaluations [6]. - It introduces a two-stage evaluation process for complex equipment, ensuring that quality is prioritized over price [6]. Monitoring and Accountability - The draft outlines clear criteria for identifying abnormal low-price bids, aiming to prevent extreme cases from occurring [7]. - Suppliers will be required to provide cost breakdowns, and the evaluation committee will verify prices against market standards [7]. Market Restructuring - The new regulations are expected to shift market dynamics, concentrating resources on high-quality companies and altering the competitive landscape between domestic and foreign brands [8][9]. - Domestic companies must transition from competing on price to emphasizing value, or risk losing market share [9]. Opportunities for Foreign Brands - Foreign brands may benefit from the new focus on quality and lifecycle costs, allowing them to leverage their technological advantages in the market [10][11]. - The policy changes will require foreign companies to adapt their pricing strategies and enhance local services to maximize their market potential [11]. Innovation and Development - The new policies are anticipated to foster innovation within the industry, encouraging companies to invest in R&D and focus on developing innovative medical devices [11]. - With a significant budget for medical equipment updates, the new regulations will direct funds towards high-quality products and services, promoting a transition to high-quality development in the industry [11].

Core Viewpoint - Thermo Fisher Scientific announced the acquisition of Clario for $8.875 billion, aiming to enhance its position in the life sciences sector and provide comprehensive solutions from laboratory to clinical settings [2]. Group 1: Industry Acquisition Landscape - The global scientific instrument industry has seen a surge in mergers and acquisitions, with major players acquiring key technologies for market expansion [3]. - Notable acquisitions include: - AMETEK acquiring FARO Technologies for $920 million to enhance precision measurement products [3]. - BD acquiring Edward's critical care division for $4.2 billion to expand its medical monitoring product line [3]. - Thermo Fisher Scientific's acquisition of Clario for $8.875 billion to strengthen its digital clinical capabilities [4]. Group 2: Strategic Directions of Acquisitions - Companies are focusing on technology integration and innovation acceleration through mergers, creating a cycle of "technology acquisition - integration - innovation - market expansion" [5]. - The life sciences sector is projected to reach a market size of $85 billion by 2028, with increasing demand for products like gene sequencers and PCR instruments [6]. - Semiconductor technology is becoming a hot topic for acquisitions, driven by geopolitical factors and the recovery of the global semiconductor industry [6]. - Digitalization and AI integration are key trends, with smart laboratory management systems improving efficiency by over 30% [6]. - Vertical integration and ecosystem building are strategies employed by leading companies like Danaher and Thermo Fisher to enhance supply chain security and customer loyalty [6]. Group 3: Emerging Trends and Market Directions - The shift from single equipment sales to system solutions and the transition from traditional technologies to intelligent and interdisciplinary integration are evident in the industry [7]. - Chinese domestic instrument companies are increasingly engaging in overseas acquisitions, marking a shift from price competition to a "domestic substitution + overseas acquisition" strategy [8]. - The capital market activity in the scientific instrument sector indicates a thriving industry, with AI-driven automation and emerging technologies like quantum sensing and MEMS leading product transformation [9]. - Future hot areas in the scientific instrument industry include life sciences and healthcare, semiconductors and high-end manufacturing, and environmental sustainability [9].

Core Insights - The General Administration of Customs plans to procure 23 microwave digestion extraction instruments with a budget of 15.43 million yuan, specifying that 22 units must be "super microwave chemical platforms" and that imported products are not accepted for bidding [1][2]. Procurement Details - The total number of projects announced by the General Administration of Customs for government procurement from July to October 2025 is 23, with a total of 1,108 instruments to be purchased, amounting to 891.548 million yuan. The types of instruments include PCR machines, X-ray fluorescence spectrometers, protein analyzers, inductively coupled plasma emission spectrometers, inductively coupled plasma mass spectrometers, ion chromatographs, gas chromatographs, gas chromatography-mass spectrometry, microwave digestion instruments, liquid chromatographs, and liquid chromatography-mass spectrometry [2]. - The procurement timeline is expected to be in September 2025 [2]. Instrument Specifications - The budget breakdown for the microwave digestion extraction instruments includes: - 1 unit at 290,000 yuan - 8 units at 680,000 yuan each - 7 units at 300,000 yuan each - 2 units at 800,000 yuan each - 5 units at 1.2 million yuan each - The warranty period for the products is one year, starting from the day of user acceptance after installation and debugging [3]. Technology Overview - The super microwave digestion system, also known as the pre-press single reaction chamber microwave digestion system, is a new technology in the field of microwave digestion. It allows sample test tubes to be inserted into a high-temperature and high-pressure reaction chamber without sealing, achieving actual working temperatures of up to 300°C and pressures of up to 200 bar. This capability simplifies the digestion process and significantly reduces operational costs, making it increasingly popular in laboratories [4].

Core Insights - The article highlights the procurement plan by the General Administration of Customs for 2025, which includes the purchase of 37 ion chromatographs with a budget of 28.21 million yuan, explicitly stating that imported products will not be accepted for bidding [2][3]. Procurement Overview - The General Administration of Customs has announced a total of 23 procurement projects from July to October 2025, involving 1,108 instruments with a total budget of 891.548 million yuan. The types of instruments include PCR machines, X-ray fluorescence spectrometers, protein analyzers, inductively coupled plasma emission spectrometers, inductively coupled plasma mass spectrometers, ion chromatographs, gas chromatographs, gas chromatography-mass spectrometry systems, microwave digestion instruments, liquid chromatographs, and liquid chromatography-mass spectrometry systems. The expected procurement time is September 2025 [3]. Ion Chromatograph Procurement Details - The procurement plan for ion chromatographs specifies the purchase of 37 units with a total budget of 28.21 million yuan. The eligibility criteria for bidders clearly state that "imported products will not be accepted," defining imported products as those that have entered China through customs and are produced outside the customs territory [2][3]. Itemized Procurement Breakdown - The detailed breakdown of the ion chromatograph procurement includes: - Package 1: - Ion Chromatograph 1: 10 units at 750,000 yuan each - Ion Chromatograph 2: 10 units at 380,000 yuan each - Ion Chromatograph 3: 3 units at 580,000 yuan each - Package 2: - Ion Chromatograph 4: 12 units at 1,200,000 yuan each - Ion Chromatograph 5: 1 unit at 300,000 yuan - Ion Chromatograph 6: 1 unit at 470,000 yuan [4].

Core Insights - The article highlights the recent announcement by the General Administration of Customs regarding six procurement intentions for laboratory instruments, with a total budget of 130 million yuan [2][3]. Procurement Overview - The procurement includes various instruments such as PCR machines, X-ray fluorescence spectrometers, sequencing machines, protein analyzers, inductively coupled plasma emission spectrometers, and microscopes, with an expected procurement date in September 2025 [3][6]. - The total budget for these instruments is 130 million yuan, indicating significant investment in laboratory capabilities [2][3]. Detailed Procurement List - **PCR Machines**: 68 units planned for procurement, budgeted at 26.02 million yuan, primarily for nucleic acid testing related to pathogens and food microorganisms [6][8]. - **X-ray Fluorescence Spectrometers**: 21 units with a budget of 29.05 million yuan, intended for qualitative and quantitative analysis of minerals, metals, and oil products [6][8]. - **Sequencing Machines**: 3 units budgeted at 5.49 million yuan, aimed at applications in transcriptome sequencing and copy number analysis [6][8]. - **Protein Analyzers**: 24 units with a budget of 9.14 million yuan, used for detecting proteins and nitrogen elements in various samples [6][8]. - **Inductively Coupled Plasma Emission Spectrometers**: 49 units budgeted at 32.51 million yuan, for multi-element analysis in various sample types [6][8]. - **Microscopes**: 67 units with a budget of 27.99 million yuan, intended for three-dimensional imaging of biological samples [6][8].

Core Viewpoint - Hubei University of Chinese Medicine has announced multiple government procurement intentions for laboratory instruments, with a total budget of 207 million yuan, focusing on advanced research equipment for traditional Chinese medicine [2][3]. Procurement Overview - The procurement includes 10 items of laboratory equipment, such as spectrometers and PCR instruments, with an expected procurement period from June to August 2025 [3]. - The total budget for the procurement is 207 million yuan [3]. Instrument Descriptions - **Spectrometer**: A precision instrument used to analyze the composition, structure, and physical-chemical properties of substances by measuring their interaction with electromagnetic waves or particles [4]. - **PCR Instrument**: Used for the in vitro amplification of specific DNA fragments, widely applied in fields such as medicine, biology, forensic science, and environmental monitoring [5]. Detailed Procurement List - The procurement list includes various instruments with specific functions, such as measuring specific elements' content and monitoring cellular physiological states [7][8]. - The budget for individual items varies, with significant allocations for advanced research equipment aimed at enhancing the capabilities of the university's research projects [8]. Institutional Background - Hubei University of Chinese Medicine, established in 1958, is the only higher education institution for traditional Chinese medicine in Hubei Province, recognized for its excellent educational standards [9]. - The university has a strong academic foundation with multiple doctoral and master's degree programs in traditional Chinese medicine and pharmacy [9]. Research and Development Achievements - The university has established several key laboratories and research centers focused on modernizing traditional Chinese medicine and has led numerous national research projects [10][11]. - Collaborations with enterprises have resulted in significant revenue generation, showcasing the practical impact of the university's research [11]. International Collaboration - The establishment of the China-Malaysia Traditional Chinese Medicine Center highlights the university's efforts to promote the internationalization of traditional Chinese medicine [12]. Talent Development - The university plans to recruit high-level research talents to enhance its research capabilities, indicating a commitment to strengthening its academic and research teams [14].

Core Viewpoint - The article discusses the launch of the "National Instrument High Quality" certification by the China Certification and Accreditation Association Testing Branch in collaboration with Beijing Xinlifang Technology Development Co., Ltd, aimed at enhancing the quality of domestic scientific instruments and addressing key issues in the industry [2]. Group 1: Certification Initiative - The initiative is part of a broader effort by the Chinese government to improve the quality of domestic instruments and solve the "bottleneck" issues in scientific instrumentation [2]. - The certification process is voluntary and is based on international quality certification standards, with the goal of promoting high-quality domestic instrument development and enhancing industry innovation capabilities [2]. - A joint working group has been established to oversee the certification process, and relevant standards have been developed, including the "General Technical Specifications for Domestic Instrument Certification" and "Implementation Requirements for Domestic Instrument Certification" [2]. Group 2: Market Demand and Government Support - The Beijing Municipal Science and Technology Commission and other departments have issued the "Beijing High-end Scientific Instrument Innovation Development Action Plan (2025-2027)," which encourages product certification to improve reliability and stability [2]. - The article highlights the importance of aligning the certification initiative with market demands and the need for high-end scientific instrument technology upgrades [2]. Group 3: Recent Market Activity - In the week of July 7-13, 2025, there were 9 reported bids related to PCR instruments, with a total bid amount of 5.667 million yuan, involving 8 brands including Qixin, Bole, Roche, and others [1].